The therapeutic modulation of immune checkpoints, such as CTLA-4 and PD-1, as well as their ligands (PD-L1 and PD-L2), has revolutionized cancer treatment by enhancing T-cell responses against tumors. Here, CTLA4 is linked to cancer.